Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/236009
Full metadata record
DC FieldValueLanguage
dc.contributor.CRUESPUNIVERSIDADE DE ESTADUAL DE CAMPINASpt_BR
dc.typeArtigo de periódicopt_BR
dc.titleSurvival And Graft-versus-host Disease In Patients Receiving Peripheral Stem Cell Compared To Bone Marrow Transplantation From Hla-matched Related Donor: Retrospective Analysis Of 334 Consecutive Patients.pt_BR
dc.contributor.authorCampregher, Paulo Vidalpt_BR
dc.contributor.authorHamerschlak, Nelsonpt_BR
dc.contributor.authorColturato, Vergilio Antonio Renzipt_BR
dc.contributor.authorMauad, Marcos Augustopt_BR
dc.contributor.authorde Souza, Mair Pedropt_BR
dc.contributor.authorBouzas, Luis Fernando da Silvapt_BR
dc.contributor.authorTavares, Rita de Cássia Bpt_BR
dc.contributor.authorBarros, José Carlospt_BR
dc.contributor.authorChiattone, Ricardopt_BR
dc.contributor.authorPaz, Alessandrapt_BR
dc.contributor.authorSilla, Luciapt_BR
dc.contributor.authorVigorito, Afonso Celsopt_BR
dc.contributor.authorMiranda, Elianept_BR
dc.contributor.authorFunke, Vaneuza Araújo Moreirapt_BR
dc.contributor.authorFlowers, Mary Evelynpt_BR
unicamp.authorAfonso Celso Vigorito, Hematology and Hemotherapy Center, Universidade Estadual de Campinas (UNICAMP), INCT do Sangue, Campinas, Brazil.pt_BR
unicamp.authorEliane Miranda, Hematology and Hemotherapy Center, Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil.pt_BR
unicamp.author.externalPaulo Vidal Campregher, Clinical Laboratory, Hospital Israelita Albert Einstein, São Paulo, Brazil.pt
unicamp.author.externalNelson Hamerschlak, Hematology and Bone Marrow Transplantation, Hospital Israelita Albert Einstein, São Paulo, Brazil.pt
unicamp.author.externalVergilio Antonio Renzi Colturato, Fundação Dr. Amaral Carvalho, Jaú, Brazil.pt
unicamp.author.externalMarcos Augusto Mauad, Clínica Segalla, Fundação Dr. Amaral Carvalho, Jaú, Brazil.pt
unicamp.author.externalMair Pedro de Souza, Hospital Amaral Carvalho, Jaú, Brazil.pt
unicamp.author.externalLuis Fernando da Silva Bouzas, Centro de Transplante de Medula Óssea (CEMO), Rio de Janeiro, Brazil.pt
unicamp.author.externalRita de Cássia B Tavares, Centro de Transplante de Medula Óssea (CEMO), Rio de Janeiro, Brazil.pt
unicamp.author.externalJosé Carlos Barros, Hematology and Oncology, Faculdade de Ciências Médicas da Santa Casa de São Paulo (FMSCSP), São Paulo, Brazil.pt
unicamp.author.externalRicardo Chiattone, Faculdade de Ciências Médicas da Santa Casa de São Paulo (FMSCSP), São Paulo, Brazil.pt
unicamp.author.externalAlessandra Paz, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.pt
unicamp.author.externalLucia Silla, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.pt
unicamp.author.externalVaneuza Araújo Moreira Funke, Universidade Federal do Paraná (UFPR), Curitiba, Brazil.pt
unicamp.author.externalMary Evelyn Flowers, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.pt
dc.subjectHaematological Neoplasmspt_BR
dc.subjectHematopoietic Stem Cell Transplantationpt_BR
dc.subjectMulticenter Studypt_BR
dc.subjectPeripheral Blood Stem Cell Transplantationpt_BR
dc.description.abstractThe objective of this study was to compare the major transplant outcomes between patients receiving hematopoietic stem cell transplantation (HSCT) from bone marrow (BM) or peripheral blood stem cells (PBSC). All consecutive HSCT patients using BM or PBSC from an HLA-matched related donors for haematological malignancies after high intensity conditioning at seven Brazilian transplant centres between January 2008 and December 2009 were retrospectively evaluated. In the study period, 334 patients were treated in the centres and included in the evaluation. The cumulative incidence of grades II-IV and III-IV acute graft-versus-host disease (GVHD) at one year was 36.7% and 9.7% for BM recipients and 34.4% and 15.1% for PBSC recipients, respectively (not statistically different). The cumulative incidence of chronic GVHD at three years was 53.7% and 79.8% (HR 1.93; 95% CI 1.38-2.69, P < 0.001) for BM and PBSC, respectively. Median overall survival was 2.85 and 2.39 years for BM and PBSC recipients, respectively (HR 1.19; 95% CI, 0.84-1.68, P = 0.34). Our results confirm previous findings of increased chronic GVHD incidence in patients receiving PBSC when compared to patients receiving BM as the graft source in HSCT. Acute GVHD incidence, progression-free survival and overall survival were not different between the groups.en
dc.relation.ispartofEuropean Journal Of Haematologypt_BR
dc.relation.ispartofabbreviationEur. J. Haematol.pt_BR
dc.date.issued2015-Novpt_BR
dc.identifier.citationEuropean Journal Of Haematology. v. 95, n. 5, p. 421-425, 2015-Nov.pt_BR
dc.language.isoengpt_BR
dc.description.volume95pt_BR
dc.description.firstpage421-425pt_BR
dc.rightsembargopt_BR
dc.sourcePubMedpt_BR
dc.identifier.issn1600-0609pt_BR
dc.identifier.doi10.1111/ejh.12508pt_BR
dc.identifier.urlhttp://www.ncbi.nlm.nih.gov/pubmed/25645430pt_BR
dc.date.available2016-05-23T19:43:36Z-
dc.date.accessioned2016-05-23T19:43:36Z-
dc.description.provenanceMade available in DSpace on 2016-05-23T19:43:36Z (GMT). No. of bitstreams: 1 pmed_25645430.pdf: 277677 bytes, checksum: 3c970061833afb0d06ff6298dcf70d62 (MD5) Previous issue date: 2015en
dc.identifier.urihttp://repositorio.unicamp.br/jspui/handle/REPOSIP/236009-
dc.identifier.idPubmed25645430pt_BR
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
pmed_25645430.pdf271.17 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.